Trump officials plan coverage for weight loss drugs under Medicare and Medicaid
The Trump administration is planning a pilot program to cover weight loss drugs under Medicaid and Medicare, the government health insurance systems for low-income individuals and retirees. The program, which was previously proposed by the Biden administration, will focus on GLP-1 drugs like Ozempic to address the chronic obesity problem in the United States. The goal of the initiative is to make these "miracle" weight loss drugs more accessible to the targeted populations, who are disproportionately affected by obesity and its associated health risks. The program is a part of the administration's efforts to tackle the growing obesity epidemic in the country.
Note: This is an AI-generated summary of the original article. For the full story, please visit the source link below.
